Replies to post #1148 on Biotech Values

[DewDiligence]

[SRDX] Corkscrew in the eye:

[This article from Medical Product Manufacturing News contains an illustration of the ocular implant being developed by private company, InnoRx, and SurModics. (See #msg-2346091 for additional background on this device.) Thanks to ‘bridgeofsighs’ on the SRDX board.]

http://www.devicelink.com/mpmn/archive/04/06/007.html

>>
Drug-delivery system developer InnoRx is creating an implantable coil to treat a number of retinal diseases. The product uses SurModics’s coating technology to release therapeutic agents into the eye. InnoRx is conducting animal studies in the first half of this year, with human clinical trials planned later in the year.

While InnoRx is in charge of the coil’s development, SurModics is providing the coating. The polymer is similar to the one used on the Cypher stent, which releases drugs within the first few months after angioplasty. The collaboration with InnoRx is SurModics’s first venture into the ophthalmology area.

“InnoRx wants to deliver drugs into the eye for maladies that often need to be treated with drugs for more than one year,” says Phil Ankeny, vice president, business development and CFO of SurModics. “We’ve taken the same polymer system [used on the Cypher stent] and adapted it to work with a different drug to deliver into the eyes. Given our experience with FDA in dealing with our proprietary coatings, we were able to provide assistance in that area as well.”
<<